Leah oversees a range of functions at Novartis Gene Therapies including Corporate Strategy, Business Development, Program Management, Translational Asset Leadership, Patient Advocacy and Policy. Her teams are responsible for sourcing external assets, ensuring they are developed strategically in a way that maximizes patient impact, and shaping the landscape externally to enable more patients to benefit from gene therapies.
Before joining Novartis in 2019, Leah led corporate strategy for AbbVie and, prior to that, for the Cystic Fibrosis Foundation. She also previously worked with the Boston Consulting Group as a Principal Consultant.
Leah holds a Bachelor of Science in molecular, cellular and developmental biology from Yale University and a doctorate in neuroscience from the University of Oxford, England. She also was named a Fulbright Scholar in virology, studying at the Pasteur Institute in Paris.